Andere Sprachen Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Aktien

688180

CNE1000041Z1

688180

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 21.05.2024			% 5 Tage	% 1. Jan.
29.22 ^CNY	-1.65%		-2.70%	-30.15%

29.04.	Shanghai Junshi Biosciences Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
25.04.	Shanghai Junshi Biosciences erhält Hongkong-Zulassung für Krebsmedikament Toripalimab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29.04.
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	25.04.
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	25.04.
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	24.04.
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	24.04.
Junshi Biosciences Gets Nod to Register Toripalimab Injection	08.04.
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07.04.
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07.04.
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07.04.
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03.04.
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02.04.
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	02.04.
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	29.03.
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29.03.
Junshi Bio's 2023 Loss Widens, Misses Estimates	26.02.
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23.02.
Junshi Biosciences Proposes Share Buyback	02.02.
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority	02.02.
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	01.02.
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Aktien

688180

CNE1000041Z1

688180

Andere Sprachen

Filter